Search

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine ® technology

Five Questions with Ai-ris Collier Our Postgraduate Education program alum discusses her research on the safety and effectiveness of administering COVID-19 mRNA vaccines to pregnant women. Ai-ris Collier, MD, is an instructor in obstetrics, gynecology, and reproductive biology at Beth Israel...

Visit Dr.Collier's Harvard Catalyst Profile for further information about her academic background, media links, research activities, funding, and clinical trials.

Dr. Collier presents "Pregnancy Immunology in Action: Maternal Immune Responses and Infant Protection"

https://www.webmd.com/vaccines/news/20250219/cm/new-studies-show-rsv-va…

A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody nirsevimab among pregnant women seen during the 2023-24 season, the first RSV season the vaccine and...

News story about the scientific premise behind our clinical trial for Long COVID patients https://clinicaltrials.gov/study/NCT06597396

Beth Israel Lahey Health (BILH) marked the 2024 International Day of Women in Science by highlighting women’s valuable contributions to science and reaffirming BILH’s commitment to greater gender diversity and inclusivity in research and innovation. Hosted by Chief Academic Officer, Gyongyi Szabo...